With a background in oncology and immunology, Dr. Brichard’s work has been focused since 1986 on immunotherapy of cancer.

He holds an M.D., a specialized master’s degree in Internal Medicine and Oncology, and a Ph.D. from Louvain University, Brussels. He further holds an MBA from the Harvard Business School.

Dr. Brichard participated actively in the pioneering work done at the Ludwig Institute for Cancer Research (Brussels Branch), where he identified several tumor antigens and started the first trials in humans with MAGE antigens. He spent several years at the Institut Curie (Paris), one of Europe’s best-known cancer centers, where he set up a cancer immunotherapy platform. In 2002 he joined GlaxoSmithKline Biologicals, where he became Senior Vice-President and had responsibility for the Immunotherapeutics Business Unit, which covered a broad, integrated approach to immunotherapy – from bench discovery through clinical development and operations to regulatory and commercial activities. In addition to this position, he served as a member of the Board of Directors at GSK Biologicals (annual sales ca. £ 7bn). Based on his experience, translated by more than 90 primary research publications and reviews, he decided to provide support to companies, organizations, institutions and individuals in the fields of immuno-oncology, auto-immunity and vaccines. Vincent is Venture Partner with LSP since 2015, active mainly in the LSP 5, LSP6 and LSP 7 funds.